ESMO-TAT 2023 - ESMO Targeted Anticancer Therapies Congress 2023: "The Home of Phase I in Oncology"
Mar 06 - Mar 08, 2023 | ParisFrance
LARVOL is not affiliated with ESMO Targeted Anticancer Therapies Congress 2023: "The Home of Phase I in Oncology" and all trademarks, logos, and brand names are property of their respective owners
Showing 20 abstracts linked to Trials
Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies
Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors
Genomic profiling to expand precision cancer medicine in the real world: The ROME trial
First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target
Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Censoring imbalance in ACIS trial for prostate cancer
Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumours or lymphomas
HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy